Clinical Trials Directory

Trials / Completed

CompletedNCT05117671

Is the EBJIS Definition of Prosthetic Joint Infection Meaningful in Our Clinical Practice?

Is the EBJIS Definition of Prosthetic Joint Infection Meaningful in Our Clinical Practice? - a Multicentric Validation Study

Status
Completed
Phase
Study type
Observational
Enrollment
1,554 (actual)
Sponsor
University Hospital, Basel, Switzerland · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This retrospective multi-center, multi-national cohort study is to validate the European Bone and Joint Infection Society (EBJIS) Definition of Prosthetic Joint Infection. Specifically, it is to analyze the outcome of the Infection Likely group and compare it to the Infection Unlikely group as well as other subgroups within previous validated definitions (Musculoskeletal Infection Society (MSIS)/International Consensus on Musculoskeletal Infection (ICM) 2013 and ICM 2018).

Detailed description

Periprosthetic joint infection (PJI) is a major burden for healthcare systems. The European Bone and Joint Infection Society (EBJIS) proposed a new set of criteria introducing a three level 'traffic light' distinction: Infection Unlikely, Infection Confirmed but also an intermediate group called Infection Likely (but nor confirmed). This retrospective multi-center, multi-national cohort study is to validate the EBJIS Definition of Prosthetic Joint Infection. Specifically, it is to analyze the outcome of the Infection Likely group and compare it to the Infection Unlikely group as well as other subgroups within previous validated definitions (Musculoskeletal Infection Society (MSIS)/International Consensus on Musculoskeletal Infection (ICM) 2013 and ICM 2018).

Conditions

Interventions

TypeNameDescription
OTHERdata collection to classify infection statusReview of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).

Timeline

Start date
2021-04-16
Primary completion
2021-08-16
Completion
2021-10-19
First posted
2021-11-11
Last updated
2024-02-28

Locations

2 sites across 2 countries: Portugal, Switzerland

Source: ClinicalTrials.gov record NCT05117671. Inclusion in this directory is not an endorsement.